Who is eligible for clinical trial NCT07761117?

Participants must meet the protocol's inclusion criteria for Heart Failure With Preserved Ejection Fraction (HFpEF). The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT07761117 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-07

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF (NCT07761117)

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants With HFpEF and HFmrEF (Elevate-HF)

🟡 Not Yet Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (17 items).

Location: Research Site — Fairhope, Alabama

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Left ventricular ejection fraction (LVEF) of \> 40% within 12 months prior to screening.
Structural heart disease evidence.
HF diagnosed with New York Heart Association (NYHA) Class II-IV at the time of screening.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
BMI \<25 kg/m² at screening.
Diabetes exclusions:
History of type 1 diabetes.
HbA1c ≥10% at screening.
Currently receiving or anticipated to receive therapeutic intervention for diabetic retinopathy and/or macular edema.
more than 1 episode of severe hypoglycemic event within 180 days prior to screening, or hypoglycemia unawareness/poor recognition.
Renal exclusions:
On a prespecified renal replacement therapy, or eGFR below a prespecified threshold at screening
Cardiovascular exclusions:
Major cardiac surgery, coronary revascularization, valvular repair/replacement, AF/AFL ablation, CRT implantation, or ICD without CRT within 90 days prior to screening, or planned after randomization.
Heart failure due to infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, genetic hypertrophic cardiomyopathy (including obstructive), or arrhythmogenic right ventricular cardiomyopathy/dysplasia.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (366 Sites)

Showing the first 25 of 366 sites.

Research Site — Fairhope, Alabama
Research Site — Beverly Hills, California
Research Site — Huntington Beach, California
Research Site — Huntington Park, California
Research Site — Loma Linda, California
Research Site — Lomita, California
Research Site — Northridge, California
Research Site — Tarzana, California
Research Site — New Haven, Connecticut
Research Site — Hialeah, Florida
Research Site — Jacksonville, Florida
Research Site — Lakeland, Florida
Research Site — Miami, Florida
Research Site — Miami, Florida
Research Site — Atlanta, Georgia
Research Site — Columbus, Georgia
Research Site — Tucker, Georgia
Research Site — Champaign, Illinois
Research Site — Park Ridge, Illinois
Research Site — Schaumburg, Illinois
Research Site — Indianapolis, Indiana
Research Site — Waterloo, Iowa
Research Site — Bossier City, Louisiana
Research Site — Covington, Louisiana
Research Site — Lafayette, Louisiana

📞 Contact the Study Coordinator

Phone: (877) 240-9479

Email: information.center@astrazeneca.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Heart Failure With Preserved Ejection Fraction (HFpEF)

Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) — Chicago, Illinois
ELEVATE-HFpEF Clinical Study — Phoenix, Arizona
Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study — Phoenix, Arizona
Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction — Gainesville, Florida

Explore by condition: All Heart Failure With Preserved Ejection Fraction (HFpEF) clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗